150 related articles for article (PubMed ID: 31427548)
1. A comparison study of HER2 protein overexpression and its gene status in breast cancer.
Md Pauzi SH; Saari HN; Roslan MR; Syed Khair Azman Jamalulil SNS; Tauan IS; Mohd Rusli FA; Aizuddin AN
Malays J Pathol; 2019 Aug; 41(2):133-138. PubMed ID: 31427548
[TBL] [Abstract][Full Text] [Related]
2. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
3. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
[TBL] [Abstract][Full Text] [Related]
4. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation.
Koopman T; van der Vegt B; Dijkstra M; Bart J; Duiker E; Wisman GBA; de Bock GH; Hollema H
Histopathology; 2018 Nov; 73(5):852-863. PubMed ID: 29989198
[TBL] [Abstract][Full Text] [Related]
5. HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slide.
Chenard MP; Wissler MP; Weingertner N; Mathelin C; Bellocq JP
Virchows Arch; 2015 Aug; 467(2):169-75. PubMed ID: 25985875
[TBL] [Abstract][Full Text] [Related]
6. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study.
Bilous M; Ades C; Armes J; Bishop J; Brown R; Cooke B; Cummings M; Farshid G; Field A; Morey A; McKenzie P; Raymond W; Robbins P; Tan L
Breast; 2003 Apr; 12(2):92-8. PubMed ID: 14659337
[TBL] [Abstract][Full Text] [Related]
7. False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.
Nunes CB; Rocha RM; Buzelin MA; Balabram D; de Souza Foureaux F; Porto SS; Gobbi H
J Clin Pathol; 2013 Nov; 66(11):946-50. PubMed ID: 23867547
[TBL] [Abstract][Full Text] [Related]
8. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
[TBL] [Abstract][Full Text] [Related]
9. Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification.
Varga Z; Tubbs RR; Moch H
PLoS One; 2014; 9(8):e105961. PubMed ID: 25153153
[TBL] [Abstract][Full Text] [Related]
10. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
11. Comparison of dual-color dual-hapten brightfield in situ hybridization (DDISH) and fluorescence in situ hybridization in breast cancer HER2 assessment.
Kosa C; Kardos L; Kovacs J; Szollosi Z
Pathol Res Pract; 2013 Mar; 209(3):147-50. PubMed ID: 23419693
[TBL] [Abstract][Full Text] [Related]
12. What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?
Curado M; Caramelo AS; Eloy C; Polónia A
Virchows Arch; 2019 Sep; 475(3):303-311. PubMed ID: 30953146
[TBL] [Abstract][Full Text] [Related]
13. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
[TBL] [Abstract][Full Text] [Related]
14. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
15. HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH.
Casterá C; Bernet L
Ann Diagn Pathol; 2020 Apr; 45():151451. PubMed ID: 31955049
[TBL] [Abstract][Full Text] [Related]
16. "HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH" Answer to the statistical issue to avoid misinterpretation.
Casterá Redal C; Bernet Vegué L
Ann Diagn Pathol; 2020 Oct; 48():151566. PubMed ID: 32763505
[TBL] [Abstract][Full Text] [Related]
17. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
[TBL] [Abstract][Full Text] [Related]
18. Detection of Gene Amplification by Multiplex Ligation-Dependent Probe Amplification in Comparison with In Situ Hybridization and Immunohistochemistry.
Tabarestani S; Ghaderian SM; Rezvani H
Asian Pac J Cancer Prev; 2015; 16(17):7997-8002. PubMed ID: 26625832
[TBL] [Abstract][Full Text] [Related]
19. Chromogenic
Ali AHM; Yahya AQ; Mohammed HL
Open Access Maced J Med Sci; 2019 Jun; 7(12):1917-1925. PubMed ID: 31406529
[TBL] [Abstract][Full Text] [Related]
20. HER2 immunohistochemical scores provide prognostic information for patients with HER2-type invasive breast cancer.
Tsai YF; Tseng LM; Lien PJ; Hsu CY; Lin YS; King KL; Wang YL; Chao TC; Liu CY; Chiu JH; Yang MH
Histopathology; 2019 Mar; 74(4):578-586. PubMed ID: 30515868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]